Antiproliferative and protein kinase binding activities of some N 6, 5'-bis-ureido 5'-amino-5'-deoxyadenosine derivatives

Nucleosides, Nucleotides and Nucleic Acids

Volumn 28, Issue 5-7, 2009, Pages 394-407

  Peterson, Matt A ^a   Oliveira, Marcelio ^a   Christiansen, Michael A ^a  

^a Brigham Young University   (United States)

Author keywords

Antiproliferative activity; Bis ureidoadenosine derivatives; Protein kinase inhibitors

Indexed keywords

ADENOSINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; N6, 5' BIS UREIDO 5' AMINO 5' DEOXYADENOSINE DERIVATIVE; P21 ACTIVATED KINASE 4; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SCREENING; ENZYME BINDING; ENZYME IMMOBILIZATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYADENOSINES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 71749103547     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770903044432     Document Type: Article

References (17)

1. Gao, Z.-G.; Duong, H.T.; Sonina, T.; Kim, S.-K.; Van Rompaey, P.; et al. A. Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists. J. Med. Chem. 2006, 49, 2689-2702.
2. Hong, C.I.; Chheda, G.B.; Dutta, S.P.; O'Grady-Curtis, A.; Tritsch, G.L. Synthesis and biological activity of analogs of naturally occurring 6-ureidopurines and their nucleosides. J. Med. Chem. 1973, 16, 139-147.
3. Sigmund, H.; Pfleiderer, W. Nucleotides Part LXXI: A new type of labelling of nucleosides and nucleotides. Helvetica Chim. Acta 2003, 86, 2299-2334.
4. Nakano, S.-I.; Uotani, Y.; Nakashima, S.; Anno, Y.; Fujii, M.; Sugimoto, N. Large stabilization of a DNA duplex by the deoxyadenosine derivatives tethering an aromatic hydrocarbon group. J. Am. Chem. Soc. 2003, 125, 8086-8087.
5. Anzai, K.; Hunt, J.B.; Zon, G. Reactions of ethyl and phenyl chloroformate with adenosine derivatives as an entry to N6-ureido-linked spin-labeled adenosine and other modified adenosines. J. Org. Chem. 1982, 47, 4281-4285.
6. Montgomery, J.A.; Thomas, H.J. Nitrosoureidonucleosides. J. Med. Chem. 1979, 22, 1109-1113.
7. Peterson, M.A.; Ke, P.; Shi, H.; Jones, C.; McDougall, B.R.; Robinson, W.E. Design, synthesis, and antiviral evaluation of some 3 -carboxymethyl-3- deoxyadenosine derivatives. Nucleos. Nucleotid. Nucl. 2007, 26, 499-519.
8. Robins, M.J.; Sarker, S.; Xie, M.; Zhang, W.; Peterson, M.A. Synthesis of 2, 3-fused (3.3.0) - butyrolactone-nucleosides and coupling with amino nucleosides to give amide-linked nucleotidedimer analogues. Tetrahedron Lett. 1996, 37, 3921-3924.
9. Peterson, M.A.; Nilsson, B.L.; Sarker, S.; Doboszewski, B.; Zhang, W.; Robins, M.J. Amide-lined ribonucleoside dimers derived from 5-amino-5deoxy- and 3-(carboxymethyl)-3-deoxynucleoside precursors. J. Org. Chem. 1999, 64, 8183-8192.
10. Holbeck, S.L. Update on NCI in vitro drug screening utilities. Eur. J. Cancer 2004, 40, 785-793.
11. Paull, K.D.; Shoemaker, R.H.; Hodes, L.; Monks, A.; Scudiero, D.A.; et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092
12. Ambit Biosciences. March, 2009http://www.ambitbio.com/
13. Fabian, M.A.; Biggs,W.H. III; Treiber, D.K.; Atteridge, C.E.; Azimioara, M.D.; et al. A Smallmoleculekinase interaction map for clinical kinase inhibitors. Nature Biotech. 2005, 23, 329-336.
14. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E., et al. A Quantitative analysis of kinase inhibitor selectivity. Nature Biotech. 2008, 26, 127-132.
15. Helms, M.W.; Packeisen, J.; August, C.; Schittek, B.; Boecker, W.; Brandt, B.H.; Buerger, H. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J. Pathol. 2005, 206, 366-376.
16. Alarmo, E.-L.; Kuukasj̈arvi, T.; Karhu, R.; Kallioniemi, A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res. Breast Cancer Res. 2007, 103, 239-246.
17. Anderson, G.J.; Darshan, D. Small-molecule dissection of BMP signaling. Nature Chem. Biol. 2008, 4, 15-16.